ONVO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 16:00):

Stats
Today's Volume	111 841
Average Volume	1.03M
Market Cap	11.85M
EPS	$0 ( 2024-02-08 )
Next earnings date	( $-0.420 ) 2024-07-11
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.480
ATR14	$0.0110 (1.07%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-17	Stern Adam K	Buy	19 607	Common Stock
2023-11-17	Milhous Alison Tjosvold	Buy	19 607	Common Stock
2023-11-17	Cohen Douglas Jay	Buy	19 607	Common Stock
2023-11-17	Murphy Keith	Buy	19 607	Common Stock
2023-11-17	Gobel David	Buy	19 607	Common Stock

INSIDER POWER
81.34
Last 90 transactions
Buy: 3 116 580 \| Sell: 414 691

Volume Correlation

Long: -0.01 (neutral)

Short: 0.96 (very strong)

Signal:(46.914) Expect same movement, but be aware

Organovo Holdings Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Organovo Holdings Inc Correlation - Currency/Commodity

0.54
( weak )

0.65
( weak )

0.00
( neutral )

0.53
( weak )

0.00
( neutral )

-0.57
( weak negative )

Organovo Holdings Inc Financials

Annual	2022
Revenue:	$370 000
Gross Profit:	$77 000.00 (20.81 %)
EPS:	$-1.980

FY	2022
Revenue:	$370 000
Gross Profit:	$77 000.00 (20.81 %)
EPS:	$-1.980

FY	2022
Revenue:	$1.50M
Gross Profit:	$1.50M (100.00 %)
EPS:	$-1.320

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.44

Financial Reports:

No articles found.

Organovo Holdings Inc

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.